Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.44 |
| ▸ | PRKCI | P41743 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7942157 | 0.86 | BACE1 (0.60) | BACE1 | |
| SCHEMBL7932770 | 0.85 | BACE1 (0.45) | BACE1PRKCIVCPHDAC1NPC1 | |
| SCHEMBL7946719 | 0.84 | BACE1 (0.43) | BACE1CASP3SENP8SENP7SENP6 | |
| SCHEMBL7941414 | 0.82 | HPGD (0.50) | BACE1PRKCICASP3SENP8SENP7 | |
| SCHEMBL7932754 | 0.82 | BACE1 (0.55) | BACE1PRKCIVCPHDAC1 | |
| SCHEMBL7944983 | 0.81 | BACE1 (0.45) | BACE1PRKCIVCPKITBRAF | |
| SCHEMBL7941231 | 0.81 | GAA (0.45) | BACE1PRKCIHDAC1KITBRAF | |
| SCHEMBL12303677 | 0.81 | BACE1 (0.49) | BACE1PRKCIVCPHDAC1KIT | |
| SCHEMBL7935774 | 0.81 | BACE1 (0.43) | BACE1PRKCIVCPHDAC1KIT | |
| SCHEMBL7945397 | 0.80 | BACE1 (0.49) | BACE1PRKCIVCPHDAC1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885PRKCI 2747/4885CASP3 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.